MedicalResearch.com Interview with: Steven Grieco, PhD Postdoctoral Scholar Xu Lab, UCI MedicalResearch.com: What is the background for this study? Response: In recent years the drug ketamine, which has been used safely as a dissociative anaesthetic for decades, has gained widespread interest in the field of psychiatry for its use as an antidepressant at low doses. In 2019 the FDA finally approved a nasal spray that delivers ketamine to patients with untreatable clinical depression.  Now, such patients go to the appropriate clinical setting and receive ketamine treatments, though this is not required daily for an effective outcome. In fact, studies have found that a single low dose ketamine treatment can result in beneficial improvements in mood that last for several days or even weeks. This suggests that ketamine treatment induces significant neural plasticity in the brain. Since the mechanisms governing this ketamine-mediated neural plasticity were not known, our group studied this using the visual cortex as a model tissue. The visual cortex has perhaps the most well-characterized patterns of neural plasticity in the brain to date, and is an excellent arena in which to test hypotheses about the mechanisms of neural plasticity. In fact, the classical antidepressant fluoxetine (Prozac), which induces neural plasticity only after long-term chronic treatment, has been studied extensivley in the visual cortex as well. (more…)